Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer

Nature Reviews Immunology

Volumn 18, Issue 12, 2018, Pages 773-789

  Jones, Simon A ^a   Jenkins, Brendan J ^b,c  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CARDIOTROPHIN 1; CARDIOTROPHIN LIKE CYTOKINE FACTOR 1; CILIARY NEUROTROPHIC FACTOR; CYTOKINE; CYTOKINE RECEPTOR; CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 11; INTERLEUKIN 27; INTERLEUKIN 31; INTERLEUKIN 6; JANUS KINASE INHIBITOR; LEUKEMIA INHIBITORY FACTOR; MONOCLONAL ANTIBODY; ONCOSTATIN M; RECOMBINANT INTERLEUKIN 11; REGULATOR OF CARTILAGE GROWTH AND DIFFERENTIATION 423; SC 144; TOCILIZUMAB; UNCLASSIFIED DRUG; GLYCOPROTEIN GP 130; IL6 PROTEIN, HUMAN; IL6ST PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; ADULT ONSET STILL DISEASE; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BACTERIAL INFECTION; BONE DISEASE; CARCINOGENESIS; CHONDROCYTE HYPERTROPHY; CHRONIC INFLAMMATION; CORONARY ARTERY ANEURYSM; CYTOKINE RELEASE SYNDROME; DRUG TARGETING; GIANT CELL ARTERITIS; HUMAN; INFECTION; INFLAMMATORY DISEASE; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; LACK OF DRUG EFFECT; MALIGNANT NEOPLASM; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYELOFIBROSIS; NONHUMAN; OSTEOARTHRITIS; OVARY CANCER; PHYLOGENY; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; IMMUNOLOGY; INFLAMMATION; METABOLISM; NEOPLASM; PATHOLOGY;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASES; CYTOKINE RECEPTOR GP130; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTERLEUKIN-6; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 85053838588     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/s41577-018-0066-7     Document Type: Review

References (268)

1. Dinarello, C. Historical insights into cytokines. Eur. J. Immunol. 37, S34–S45 (2007).
2. Garbers, C. et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev. 23, 85–97 (2012).
3. Choy, E. H., Kavanaugh, A. F. & Jones, S. A. The problem of choice: current biologic agents and future prospects in RA. Nat. Rev. Rheumatol. 9, 154–163 (2013).
4. Ernst, M. & Putoczki, T. L. Targeting IL-11 signaling in colon cancer. Oncotarget 4, 1860–1861 (2013).
5. Hunter, C. A. & Jones, S. A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16, 448–457 (2015).
6. Johnson, D. E., O’Keefe, R. A. & Grandis, J. R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15, 234–248 (2018).
7. McInnes, I. B. & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7, 429–442 (2007).
8. Schett, G., Elewaut, D., McInnes, I. B., Dayer, J. M. & Neurath, M. F. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat. Med. 19, 822–824 (2013). References 7 and 8 discuss the context-dependent nature of inflammation and the importance of understanding these processes in determining the appropriate course of biological drug therapy.
9. Villarino, A. V., Kanno, Y. & O’Shea, J. J. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat. Immunol. 18, 374–384 (2017).This is an excellent review on the mechanisms of JAK–STAT signalling and an introduction to new methodologies relevant to the study of these processes.
10. Nishimoto, N. et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106, 2627–2632 (2005).
11. Villiger, P. M. et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 387, 1921–1927 (2016).
12. Nishimoto, N. et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50, 1761–1769 (2004).
13. Bordon, Y. Immunometabolism: IL-6, the resistance fighter. Nat. Rev. Immunol. 14, 282–283 (2014). This is an excellent commentary on the importance of IL-6 in metabolism and immune homeostasis.
14. Kishimoto, T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res. Ther. 8, S2 (2006).
15. Rose-John, S. Interleukin-6 family cytokines. Cold Spring Harb. Perspect. Biol. 10, a028415 (2018).
16. Heinrich, P. C. et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374, 1–20 (2003). This article provides a comprehensive overview of the signal transduction mechanisms employed by the IL-6 cytokine family.
17. Garbers, C. & Rose-John, S. Dissecting interleukin-6 classic- and trans-signaling in inflammation and cancer. Methods Mol. Biol. 1725, 127–140 (2018).
18. Ferretti, E., Corcione, A. & Pistoia, V. The IL-31/IL-31 receptor axis: general features and role in tumor microenvironment. J. Leukoc. Biol. 102, 711–717 (2017).
19. Hermanns, H. Oncostatin M and interleukin-31: cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev. 26, 545–558 (2015).
20. Jones, L. L. & Vignali, D. A. A. Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily. Immunol. Res. 51, 5–14 (2011).
21. Brocker, C., Thompson, D., Matsumoto, A., Nebert, D. W. & Vasiliou, V. Evolutionary divergence and functions of the human interleukin (IL) gene family. Hum. Genom. 5, 30–55 (2010).
22. Huising, M. O., Kruiswijk, C. P. & Flik, G. Phylogeny and evolution of class-I helical cytokines. J. Endocrinol. 189, 1–25 (2006).
23. Hunter, C. A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol. 5, 521–531 (2005).
24. Wang, X. et al. Interleukin (IL)-39 [IL-23p19/Epstein-Barr virus-induced 3 (Ebi3)] induces differentiation/expansion of neutrophils in lupus-prone mice. Clin. Exp. Immunol. 186, 144–156 (2016).
25. Ning-Wei, Z. Interleukin (IL)-35 is raising our expectations. Rev. Med. Chil. 138, 758–766 (2010).
26. Collison, L. W. et al. The composition and signaling of the IL-35 receptor are unconventional. Nat. Immunol. 13, 290–299 (2012).
27. Stumhofer, J. S. et al. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat. Immunol. 11, 1119–1126 (2010).
28. Yoshida, K. et al. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc. Natl Acad. Sci. USA 93, 407–411 (1996).
29. Heinrich, P. C., Behrmann, I., Müller-Newen, G., Schaper, F. & Graeve, L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334, 297–314 (1998).
30. −/− mouse.
31. Escary, J. L., Perreau, J., Dumenil, D., Ezine, S. & Brulet, P. Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation. Nature 363, 361–364 (1993).
32. Schuster, B. et al. Signaling of human ciliary neurotrophic factor (CNTF) revisited. The interleukin-6 receptor can serve as an alpha-receptor for CTNF. J. Biol. Chem. 278, 9528–9535 (2003).
33. Nicolaou, A. et al. The ADAM17 metalloproteinase maintains arterial elasticity. Thromb. Haemost. 118, 210–213 (2018).
34. Prystaz, K. et al. Distinct effects of IL-6 classic and trans-signaling in bone fracture healing. Am. J. Pathol. 188, 474–490 (2018).
35. Yan, J. et al. Interleukin-30 (IL27p28) alleviates experimental sepsis by modulating cytokine profile in NKT cells. J. Hepatol. 64, 1128–1136 (2016).
36. Garbers, C. et al. An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer. J. Biol. Chem. 288, 4346–4354 (2013).
37. Jones, S. A., Scheller, J. & Rose-John, S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 121, 3375–3383 (2011).
38. Chalaris, A., Garbers, C., Rabe, B., Rose-John, S. & Scheller, J. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur. J. Cell Biol. 90, 484–494 (2011).
39. Jones, S. A. Directing transition from innate to acquired immunity: defining a role for IL-6. J. Immunol. 175, 3463–3468 (2005).
40. Jones, S. A., Horiuchi, S., Topley, N., Yamamoto, N. & Fuller, G. M. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J. 15, 43–58 (2001).
41. Rose-John, S. & Heinrich, P. C. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J. 300, 281–290 (1994).
42. Peters, M. et al. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J. Exp. Med. 183, 1399–1406 (1996).
43. Gearing, D. P. & Cosman, D. Homology of the p40 subunit of natural killer cell stimulatory factor (NKSF) with the extracellular domain of the interleukin-6 receptor. Cell 66, 9–10 (1991).
44. Chehboun, S. et al. Epstein-Barr virus-induced gene 3 (EBI3) can mediate IL-6 trans-signaling. J. Biol. Chem. 292, 6644–6656 (2017).
45. Davis, S. et al. Released form of CNTF receptor alpha component as a soluble mediator of CNTF responses. Science 259, 1736–1739 (1993).
46. Lokau, J. et al. Proteolytic cleavage governs interleukin-11 trans-signaling. Cell Rep. 14, 1761–1773 (2016).
47. Yamada, O., Ozaki, K., Akiyama, M. & Kawauchi, K. JAK-STAT and JAK-PI3K-mTORC1 pathways regulate telomerase transcriptionally and posttranslationally in ATL cells. Mol. Cancer Ther. 11, 1112–1121 (2012).
48. Thiem, S. et al. mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. J. Clin. Invest. 123, 767–781 (2013).
49. Taniguchi, K. et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 519, 57–62 (2015). This study offers new insights into gp130 control of tissue regeneration and maintenance of immune homeostasis.
50. Holland, S. M. et al. STAT3 mutations in the hyper-IgE syndrome. N. Engl. J. Med. 357, 1608–1619 (2007).
51. Kreins, A. Y. et al. Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome. J. Exp. Med. 212, 1641–1662 (2015).
52. Ernst, M. & Jenkins, B. J. Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet. 20, 23–32 (2004).
53. Freeman, A. F. & Holland, S. M. Clinical manifestations of hyper IgE syndromes. Dis. Markers 29, 123–130 (2010).
54. Rebouissou, S. et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457, 200–204 (2009).
55. Stark, G. R. & Darnell, J. E. Jr. The JAK-STAT pathway at twenty. Immunity 36, 503–514 (2012). This is a comprehensive overview including a historical perspective on the modulation of JAK–STAT signalling and its implications on cytokine biology.
56. Yoshimura, A., Naka, T. & Kubo, M. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 7, 454–465 (2007).
57. Boulay, J. L., O’Shea, J. J. & Paul, W. E. Molecular phylogeny within type I cytokines and their cognate receptors. Immunity 19, 159–163 (2003).
58. Yang, J. et al. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev. 21, 1396–1408 (2007).
59. Löffler, D. et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 110, 1330–1333 (2007).
60. Yu, L. et al. Clinical utility of a STAT3-regulated miRNA-200 family signature with prognostic potential in early gastric cancer. Clin. Cancer Res. 24, 1459–1472 (2018).
61. Qing, Y. & Stark, G. R. Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J. Biol. Chem. 279, 41679–41685 (2004).
62. Costa-Pereira, A. P. et al. Mutational switch of an IL-6 response to an interferon-gamma-like response. Proc. Natl Acad. Sci. USA 99, 8043–8047 (2002).
63. Yang, X. P. et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat. Immunol. 12, 247–254 (2011).
64. Avalle, L., Pensa, S., Regis, G., Novelli, F. & Poli, V. STAT1 and STAT3 in tumorigenesis: a matter of balance. JAKSTAT 1, 65–72 (2012).
65. Hirahara, K. et al. Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev. 21, 425–434 (2010).
66. + T cells and illustrates the relationship between cytokine activation of STAT1 and STAT3.
67. Hunter, C. A. & Kastelein, R. Interleukin-27: balancing protective and pathological immunity. Immunity 37, 960–969 (2012).
68. Jenkins, B. J. Transcriptional regulation of pattern recognition receptors by Jak/STAT signaling, and the implications for disease pathogenesis. J. Interferon Cytokine Res. 34, 750–758 (2014).
69. Guo, R. F. & Ward, P. A. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23, 821–852 (2005).
70. Greenhill, C. J. et al. IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. J. Immunol. 186, 1199–1208 (2011).
71. Riedemann, N. C. et al. Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis. FASEB J. 18, 370–372 (2004).
72. Riedemann, N. C. et al. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J. Immunol. 170, 503–507 (2003).
73. Strey, C. W. et al. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J. Exp. Med. 198, 913–923 (2003).
74. Mansell, A. & Jenkins, B. J. Dangerous liaisons between interleukin-6 cytokine and toll-like receptor families: a potent combination in inflammation and cancer. Cytokine Growth Factor Rev. 24, 249–256 (2013).
75. Silver, J. S., Stumhofer, J. S., Passos, S., Ernst, M. & Hunter, C. A. IL-6 mediates the susceptibility of glycoprotein 130 hypermorphs to Toxoplasma gondii. J. Immunol. 187, 350–360 (2011).
76. Larrea, E. et al. Oncostatin M enhances the antiviral effects of type I interferon and activates immunostimulatory functions in liver epithelial cells. J. Virol. 83, 3298–3311 (2009).
77. Patterson, B. K. et al. Leukemia inhibitory factor inhibits HIV-1 replication and is upregulated in placentae from nontransmitting women. J. Clin. Invest. 107, 287–294 (2001).
78. Modur, V. et al. Oncostatin M is a proinflammatory mediator. in vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J. Clin. Invest. 100, 158–168 (1997).
79. Ayaub, E. A. et al. Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycin-induced lung fibrosis. Sci. Rep. 7, 13281 (2017).
80. Chu, D. K. et al. Therapeutic potential of anti-IL-6 therapies for granulocytic airway inflammation in asthma. Allergy Asthma Clin. Immunol. 11, 14 (2015).
81. Chen, Q. et al. IL-11 receptor alpha in the pathogenesis of IL-13-induced inflammation and remodeling. J. Immunol. 174, 2305–2313 (2005).
82. Dixit, A. et al. Frontline science: proliferation of Ly6C(+) monocytes during urinary tract infections is regulated by IL-6 trans-signaling. J. Leukoc. Biol. 103, 13–22 (2018).
83. Xing, Z. et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. 101, 311–320 (1998).
84. Romani, L. et al. Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J. Exp. Med. 183, 1345–1355 (1996).
85. Jones, S. A., Fraser, D. J., Fielding, C. A. & Jones, G. W. Interleukin-6 in renal disease and therapy. Nephrol. Dial Transplant 30, 564–574 (2015).
86. Garbers, C. et al. The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases. Biochim. Biophys. Acta 1842, 1485–1494 (2014).
87. IL6R Genetics Consortium Emerging Risk Factors Collaboration et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379, 1205–1213 (2012). References 89 and 90 emphasize the clinical importance of genetic variants within the IL-6R system.
88. Ferreira, R. C. et al. Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. PLOS Genet. 9, e1003444 (2013).
89. Wong, P. K. et al. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum. 54, 158–168 (2006).
90. Sims, N. A. gp130 signaling in bone cell biology: multiple roles revealed by analysis of genetically altered mice. Mol. Cell Endocrinol. 310, 30–39 (2009).
91. Nakamura, K., Nonaka, H., Saito, H., Tanaka, M. & Miyajima, A. Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice. Hepatology 39, 635–644 (2004).
92. Hams, E. et al. Oncostatin M receptor-beta signaling limits monocytic cell recruitment in acute inflammation. J. Immunol. 181, 2174–2180 (2008).
93. Esashi, E. et al. Oncostatin M deficiency leads to thymic hypoplasia, accumulation of apoptotic thymocytes and glomerulonephritis. Eur. J. Immunol. 39, 1664–1670 (2009).
94. Yoshida, H. & Hunter, C. A. The immunobiology of interleukin-27. Annu. Rev. Immunol. 33, 417–443 (2015). This is an excellent commentary on the biological properties of IL-27.
95. Villarino, A. V. et al. IL-27 limits IL-2 production during Th1 differentiation. J. Immunol. 176, 237–247 (2006).
96. Hall, A. O. et al. The cytokines interleukin 27 and interferon-gamma promote distinct Treg cell populations required to limit infection-induced pathology. Immunity 37, 511–523 (2012).
97. Stumhofer, J. S. et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 8, 1363–1371 (2007).
98. Villarino, A. et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 19, 645–655 (2003).
99. Young, A. et al. Cutting edge: suppression of GM-CSF expression in murine and human T cells by IL-27. J. Immunol. 189, 2079–2083 (2012).
100. Stumhofer, J. S. et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 7, 937–945 (2006). This study provides an early example of how IL-27 may counteract some of the activities controlled by IL-6.
101. Nosko, A. et al. T-Bet enhances regulatory T cell fitness and directs control of Th1 responses in crescentic GN. J. Am. Soc. Nephrol. 28, 185–196 (2017).
102. Fielding, C. A. et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40, 40–50 (2014).
103. Iwakura, Y., Ishigame, H., Saijo, S. & Nakae, S. Functional specialization of interleukin-17 family members. Immunity 34, 149–162 (2011).
104. Liu, L. et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J. Exp. Med. 208, 1635–1648 (2011).
105. Dileepan, T. et al. Robust antigen specific th17 T cell response to group A Streptococcus is dependent on IL-6 and intranasal route of infection. PLOS Pathog. 7, e1002252 (2011).
106. Diveu, C. et al. IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J. Immunol. 182, 5748–5756 (2009).
107. Son, H.-J. et al. Oncostatin M suppresses activation of IL-17/Th17 via SOCS3 regulation in CD4(+) T cells. J. Immunol. 198, 1484–1491 (2017).
108. Zhang, X. et al. IL-11 induces Th17 cell responses in patients with early relapsing-remitting multiple sclerosis. J. Immunol. 194, 5139–5149 (2015).
109. Lucas, S., Ghilardi, N., Li, J. & de Sauvage, F. J. IL-27 regulates IL-12 responsiveness of naïve CD4+ T cells through Stat1-dependent and -independent mechanisms. Proc. Natl Acad. Sci. USA 100, 15047–15052 (2003).
110. Peters, A. et al. IL-27 induces Th17 differentiation in the absence of STAT1 signaling. J. Immunol. 195, 4144–4153 (2015).
111. Jones, G. W. et al. Exacerbated inflammatory arthritis in response to hyperactive gp130 signalling is independent of IL-17A. Ann. Rheum. Dis. 72, 1738–1742 (2013).
112. Quintana, F. J. et al. Aiolos promotes TH17 differentiation by directly silencing Il2 expression. Nat. Immunol. 13, 770–777 (2012).
113. Kimura, A., Naka, T., Nohara, K., Fujii-Kuriyama, Y. & Kishimoto, T. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc. Natl Acad. Sci. USA 105, 9721–9726 (2008).
114. Moon, S. J. et al. In vivo action of IL-27: reciprocal regulation of Th17 and Treg cells in collagen-induced arthritis. Exp. Mol. Med. 45, e46 (2013).
115. Korn, T. et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc. Natl Acad. Sci. USA 105, 18460–18465 (2008).
116. Pasare, C. & Medzhitov, R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299, 1033–1036 (2003).
117. Vasconcellos, R., Carter, N. A., Rosser, E. C. & Mauri, C. IL-12p35 subunit contributes to autoimmunity by limiting IL-27-driven regulatory responses. J. Immunol. 187, 3402–3412 (2011).
118. Fujimoto, M. et al. The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells. J. Immunol. 186, 32–40 (2011).
119. Komori, T. & Morikawa, Y. Oncostatin M in the development of metabolic syndrome and its potential as a novel therapeutic target. Anat. Sci. Int. 93, 169–176 (2017).
120. Mauer, J. et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat. Immunol. 15, 423–430 (2014).
121. Kraakman, M. J. et al. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab. 21, 403–416 (2015).
122. Petruzzelli, M. et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20, 433–447 (2014).
123. Flint, T. R. et al. Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity. Cell Metab. 24, 672–684 (2016). References 122–126 describe the importance of IL-6 cytokines in metabolism.
124. McFarland-Mancini, M. M. et al. Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. J. Immunol. 184, 7219–7228 (2010).
125. Ramsay, A. J. et al. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 264, 561–563 (1994).
126. Kallen, K. J. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim. Biophys. Acta 1592, 323–343 (2002).
127. Mozaffarian, A. et al. Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J. Immunol. 181, 7243–7253 (2008).
128. Ruzicka, T. et al. Anti-interleukin-31 receptor A antibody for atopic dermatitis. N. Engl. J. Med. 376, 826–835 (2017).
129. Schafer, S. et al. IL-11 is a crucial determinant of cardiovascular fibrosis. Nature 552, 110–115 (2017).
130. Hong, F. et al. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J. Clin. Invest. 110, 1503–1513 (2002).
131. Zhang, W. et al. Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage. Hypertension 59, 136–144 (2012).
132. Booth, A. J. et al. Connective tissue growth factor promotes fibrosis downstream of TGFbeta and IL-6 in chronic cardiac allograft rejection. Am. J. Transplant 10, 220–230 (2010).
133. Nakashima, C., Otsuka, A. & Kabashima, K. Interleukin-31 and interleukin-31 receptor-new therapeutic targets for atopic dermatitis. Exp. Dermatol. 27, 327–331 (2018).
134. Zhang, X. L., Topley, N., Ito, T. & Phillips, A. Interleukin-6 regulation of transforming growth factor (TGF)-beta receptor compartmentalization and turnover enhances TGF-beta1 signaling. J. Biol. Chem. 280, 12239–12245 (2005).
135. Neveu, W. A. et al. Elevation of IL-6 in the allergic asthmatic airway is independent of inflammation but associates with loss of central airway function. Respir. Res. 11, 28 (2010).
136. Simmons, E. M. et al. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int. 65, 1357–1365 (2004).
137. Horii, Y. et al. Involvement of IL-6 in mesangial proliferative glomerulonephritis. J. Immunol. 143, 3949–3955 (1989).
138. Nechemia-Arbely, Y. et al. IL-6/IL-6R axis plays a critical role in acute kidney injury. J. Am. Soc. Nephrol. 19, 1106–1115 (2008).
139. Grivennikov, S. et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103–113 (2009).
140. Qiu, Z., Fujimura, M., Kurashima, K., Nakao, S. & Mukaida, N. Enhanced airway inflammation and decreased subepithelial fibrosis in interleukin 6-deficient mice following chronic exposure to aerosolized antigen. Clin. Exp. Allergy 34, 1321–1328 (2004).
141. Ivashkiv, L. B. & Hu, X. The JAK/STAT pathway in rheumatoid arthritis: pathogenic or protective? Arthritis Rheum. 48, 2092–2096 (2003).
142. Walker, J. G. & Smith, M. D. The Jak-STAT pathway in rheumatoid arthritis. J. Rheumatol 32, 1650–1653 (2005).
143. Nowell, M. A. et al. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 54, 2084–2095 (2006).
144. Nowell, M. A. et al. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J. Immunol. 182, 613–622 (2009).
145. Atsumi, T. et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J. Exp. Med. 196, 979–990 (2002).
146. Jenkins, B. J. et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat. Med. 11, 845–852 (2005).
147. Fielding, C. A. et al. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J. Immunol. 181, 2189–2195 (2008).
148. Romas, E. et al. The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J. Exp. Med. 183, 2581–2291 (1996).
149. Le Goff, B. et al. Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in synovial fibroblasts. Cytokine 68, 101–109 (2014).
150. Matsushita, K. et al. LIF/STAT3/SOCS3 signaling pathway in murine bone marrow stromal cells suppresses osteoblast differentiation. J. Cell. Biochem. 115, 1262–1268 (2014).
151. Walker, E. C. et al. Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J. Clin. Invest. 120, 582–592 (2010).
152. Kalliolias, G. D., Zhao, B., Triantafyllopoulou, A., Park-Min, K. H. & Ivashkiv, L. B. Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. Arthritis Rheum. 62, 402–413 (2010).
153. Udagawa, N. et al. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J. Exp. Med. 182, 1461–1468 (1995).
154. Nowell, M. A. et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J. Immunol. 171, 3202–3209 (2003). This study provides an early example of the importance of cytokine trans -signalling in chronic inflammatory disease.
155. Richards, P. J. et al. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum. 54, 1662–1672 (2006).
156. Desgeorges, A. et al. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J. Rheumatol 24, 1510–1516 (1997).
157. Kotake, S. et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res. 11, 88–95 (1996).
158. Robak, T., Gladalska, A., Stepien, H. & Robak, E. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm. 7, 347–353 (1998).
159. Meka, R. R., Venkatesha, S. H., Dudics, S., Acharya, B. & Moudgil, K. D. IL-27-induced modulation of autoimmunity and its therapeutic potential. Autoimmun Rev. 14, 1131–1141 (2015).
160. Pitzalis, C., Jones, G. W., Bombardieri, M. & Jones, S. A. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat. Rev. Immunol. 14, 447–462 (2014).
161. Jones, G. W. et al. Interleukin-27 inhibits ectopic lymphoid-like structure development in early inflammatory arthritis. J. Exp. Med. 212, 1793–1802 (2015).
162. Orr, C. et al. Synovial tissue research: a state-of-the-art review. Nat. Rev. Rheumatol 13, 463–475 (2017).
163. Rangel-Moreno, J. et al. The development of inducible bronchus-associated lymphoid tissue depends on IL-17. Nat. Immunol. 12, 639–646 (2011).
164. Peters, A. et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 35, 986–996 (2011).
165. Ma, C. S., Deenick, E. K., Batten, M. & Tangye, S. G. The origins, function, and regulation of T follicular helper cells. J. Exp. Med. 209, 1241–1253 (2012).
166. Taniguchi, K. & Karin, M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin. Immunol. 26, 54–74 (2014).
167. Yu, H., Lee, H., Herrmann, A., Buettner, R. & Jove, R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer 14, 736–746 (2014).
168. Li, N., Grivennikov, S. I. & Karin, M. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 19, 429–431 (2011).
169. Tye, H. et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 22, 466–478 (2012). This study presents the seminal discovery that IL-6 family cytokines (via JAK–STAT signalling) elicit crosstalk with pattern recognition receptors to promote tumorigenesis.
170. Ernst, M. et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J. Clin. Invest. 118, 1727–1738 (2008).
171. Sullivan, N. J. et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 28, 2940–2947 (2009).
172. Gawlik-Rzemieniewska, N. & Bednarek, I. The role of NANOG transcriptional factor in the development of malignant phenotype of cancer cells. Cancer Biol. Ther. 17, 1–10 (2016).
173. Johnstone, C. N., Chand, A., Putoczki, T. L. & Ernst, M. Emerging roles for IL-11 signaling in cancer development and progression: focus on breast cancer. Cytokine Growth Factor Rev. 26, 489–498 (2015).
174. Winship, A. L., Van Sinderen, M., Donoghue, J., Rainczuk, K. & Dimitriadis, E. Targeting interleukin-11 receptor-α impairs human endometrial cancer cell proliferation and invasion in vitro and reduces tumor growth and metastasis in vivo. Mol. Cancer Ther. 15, 720–730 (2016).
175. Li, X. et al. LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway. Oncotarget 5, 788–801 (2014).
176. Yue, X. et al. Leukemia inhibitory factor promotes EMT through STAT3-dependent miR-21 induction. Oncotarget 7, 3777–3790 (2016).
177. Junk, D. J. et al. Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling. Oncogene 36, 4001–4013 (2017).
178. Zeng, H. et al. Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylase inhibitors in breast cancer. Cancer Cell 30, 459–473 (2016).
179. Shien, K. et al. JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer. Mol. Cancer Ther. 16, 2234–2245 (2017).
180. Pencik, J. et al. STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nat. Commun. 6, 7736 (2015).
181. Cocco, C. et al. Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin. Cancer Res. 16, 4188–4197 (2010).
182. Pan, C. M., Wang, M. L., Chiou, S. H., Chen, H. Y. & Wu, C. W. Oncostatin M suppresses metastasis of lung adenocarcinoma by inhibiting SLUG expression through coordination of STATs and PIASs signalings. Oncotarget 7, 60395–60406 (2016).
183. Tsukamoto, H. et al. Immune-suppressive effects of interleukin-6 on T cell-mediated anti-tumor immunity. Cancer Sci. 109, 523–530 (2018).
184. Xu, D. H. et al. The role of IL-11 in immunity and cancer. Cancer Lett. 373, 156–163 (2016).
185. Shiga, K. et al. Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers (Basel) 7, 2443–2458 (2015).
186. Fabbi, M., Carbotti, G. & Ferrini, S. Dual roles of IL-27 in cancer biology and immunotherapy. Mediators Inflamm. 2017, 3958069 (2017).
187. Garbers, C., Heink, S., Korn, T. & Rose-John, S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat. Rev. Drug Discov. 17, 395–412 (2018).
188. Klein, B., Lu, Z. Y., Gaillard, J. P., Harousseau, J. L. & Bataille, R. Inhibiting IL-6 in human multiple myeloma. Curr. Top. Microbiol. Immunol. 182, 237–244 (1992).
189. Lu, Z. Y. et al. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur. J. Immunol. 22, 2819–2824 (1992).
190. de Boysson, H., Février, J., Nicolle, A., Auzary, C. & Geffray, L. Tocilizumab in the treatment of the adult-onset Still’s disease: current clinical evidence. Clin. Rheumatol 32, 141–147 (2013).
191. Bae, S. C. & Lee, Y. H. Comparison of the efficacy and tolerability of tocilizumab, sarilumab, and sirukumab in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Clin. Rheumatol 37, 1471–1479 (2018).
192. De Benedetti, F. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367, 2385–2395 (2012).
193. Genovese, M. C. et al. Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. Rheumatology 57, 1423–1431 (2018).
194. Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739–748 (2018).
195. Tanaka, Y. & Martin Mola, E. IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. Ann. Rheum. Dis. 73, 1595–1597 (2014). This is a review article discussing the activities of IL-6-directed biological drug therapies with TNF-targeting interventions.
196. Varghese, J. N. et al. Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain. Proc. Natl Acad. Sci. USA 99, 15959–15964 (2002).
197. Adams, R. et al. Discovery of a junctional epitope antibody that stabilizes IL-6 and gp80 protein:protein interaction and modulates its downstream signaling. Sci. Rep. 7, 37716 (2017).
198. Lacroix, M. et al. Novel insights into interleukin 6 (IL-6) cis- and trans-signaling pathways by differentially manipulating the assembly of the IL-6 signaling complex. J. Biol. Chem. 290, 26943–26953 (2015).
199. Baran, P. et al. The balance of Interleukin (IL)-6, IL-6:soluble IL-6 receptor (IL-6R) and IL-6:sIL-6R:sgp130 complexes allows simultaneous classic and trans-signaling. J. Biol. Chem. 293, 6762–6775 (2018).
200. Smolen, J. S. et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann. Rheum. Dis. 72, 482–492 (2013).
201. Schoels, M. M. et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann. Rheum. Dis. 72, 583–589 (2013).
202. Nishimoto, N. et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann. Rheum. Dis. 66, 1162–1167 (2007).
203. Yokota, S. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371, 998–1006 (2008).
204. Yokota, S. et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J. Rheumatol 41, 759–767 (2014).
205. Wright, H. L., Cross, A. L., Edwards, S. W. & Moots, R. J. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology 53, 1321–1331 (2014).
206. Liu, F., Poursine-Laurent, J., Wu, H. Y. & Link, D. C. Interleukin-6 and the granulocyte colony-stimulating factor receptor are major independent regulators of granulopoiesis in vivo but are not required for lineage commitment or terminal differentiation. Blood 90, 2583–2590 (1997).
207. Navarini, A. A., French, L. E. & Hofbauer, G. F. Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection. J. Allergy Clin. Immunol. 128, 1128–1130 (2011).
208. Rose-John, S., Winthrop, K. & Calabrese, L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat. Rev. Rheumatol. 13, 399–409 (2017).
209. Puel, A. et al. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J. Immunol. 180, 647–654 (2008).
210. Genovese, M. C. et al. Transaminase levels and hepatic events during tocilizumab treatment: pooled analysis of long-term clinical trial safety data in rheumatoid arthritis. Arthritis Rheumatol. 69, 1751–1761 (2017).
211. Choy, E., Ganeshalingam, K., Semb, A. G., Szekanecz, Z. & Nurmohamed, M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology 53, 2143–2154 (2014). This study provides a clinical perspective on the link between systemic chronic inflammation and changes in cardiovascular risk.
212. Gabay, C. et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 75, 1806–1812 (2016).
213. Tamura, T. et al. Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. J. Clin. Invest. 128, 1956–1970 (2018).
214. Kim, S. C. et al. Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study. Arthritis Rheumatol. 69, 1154–1164 (2017).
215. Nozawa, T., Imagawa, T. & Ito, S. Coronary-artery aneurysm in tocilizumab-treated children with Kawasaki’s Disease. N. Engl. J. Med. 377, 1894–1896 (2017).
216. Smeeth, L. et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N. Engl. J. Med. 351, 2611–2618 (2004).
217. Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).
218. Bayliss, T. J., Smith, J. T., Schuster, M., Dragnev, K. H. & Rigas, J. R. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin. Biol. Ther. 11, 1663–1668 (2011).
219. Ando, K. et al. Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J. Clin. Oncol. 31, e69–72 (2013).
220. Heo, T. H., Wahler, J. & Suh, N. Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer. Oncotarget 7, 15460–15473 (2016).
221. Teachey, D. T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664–679 (2016).
222. Chen, F. et al. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. J. Immunol. Methods 434, 1–8 (2016).
223. Choy, E. H. et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials. Arthritis Res. Ther. 15, R132–R132 (2013).
224. West, N. R. et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat. Med. 23, 579–589 (2017). This study showcases the inflammatory role of OSM in inflammatory bowel disease and its potential utility as a clinical biomarker for therapy.
225. Dwaine, F. E. & Christopher, G. T. Intracompartmental delivery of CNTF as therapy for Huntingtons disease and retinitis pigmentosa. Curr. Gene Ther. 6, 147–159 (2006).
226. Lipinski, D. M. et al. CNTF gene therapy confers lifelong neuroprotection in a mouse model of human retinitis pigmentosa. Mol. Ther. 23, 1308–1319 (2015).
227. Sieving, P. A. et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc. Natl Acad. Sci. USA 103, 3896–3901 (2006).
228. Moreland, L. et al. Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. Arthritis Res. 3, 247–252 (2001).
229. Metcalfe, S. M. LIF in the regulation of T cell fate and as a potential therapeutic. Genes Immun. 12, 157 (2011).
230. Niedbala, W. et al. Interleukin 27 attenuates collagen-induced arthritis. Ann. Rheum. Dis. 67, 1474–1479 (2008).
231. Kalliolias, G. D. & Ivashkiv, L. B. IL-27 activates human monocytes via STAT1 and suppresses IL-10 production but the inflammatory functions of IL-27 are abrogated by TLRs and p38. J. Immunol. 180, 6325–6333 (2008).
232. Shkhyan, R. et al. Drug-induced modulation of gp130 signalling prevents articular cartilage degeneration and promotes repair. Ann. Rheum. Dis. 77, 760–769 (2018).
233. Xu, S., Grande, F., Garofalo, A. & Neamati, N. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. Mol. Cancer Ther. 12, 937–949 (2013).
234. Hayashi, M. et al. Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130. Proc. Natl Acad. Sci. USA 99, 14728–14733 (2002).
235. Hong, S. S. et al. A novel small-molecule inhibitor targeting the IL-6 receptor beta subunit, glycoprotein 130. J. Immunol. 195, 237–245 (2015).
236. Schwartz, D. M. et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov. 17, 78 (2017).
237. Collins, A. S. et al. Hepatitis C virus (HCV)-induced suppressor of cytokine signaling (SOCS) 3 regulates proinflammatory TNF-alpha responses. J. Leukoc. Biol. 96, 255–263 (2014).
238. Shouda, T. et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J. Clin. Invest. 108, 1781–1178 (2001).
239. Hong, D. et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci. Transl Med. 7, 314ra185 (2015).
240. Zhang, Q. et al. Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. Blood 127, 1687–1700 (2016).
241. Siveen, K. S. et al. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim. Biophys. Acta 1845, 136–154 (2014).
242. Stephens, J. M. & Elks, C. M. Oncostatin M: potential implications for malignancy and metabolism. Curr. Pharm. Des. 23, 3645–3657 (2017).
243. Covarrubias, A. J. & Horng, T. IL-6 strikes a balance in metabolic inflammation. Cell Metab. 19, 898–899 (2014).
244. Komori, T., Tanaka, M., Senba, E., Miyajima, A. & Morikawa, Y. Lack of oncostatin M receptor β leads to adipose tissue inflammation and insulin resistance by switching macrophage phenotype. J. Biol. Chem. 288, 21861–21875 (2013).
245. Vigne, S. et al. IL-27-induced type 1 regulatory T-cells produce oxysterols that constrain IL-10 production. Front. Immunol. 8, 1184 (2017).
246. Andrews, N. C. Disorders of iron metabolism. N. Engl. J. Med. 341, 1986–1995 (1999).
247. Isaacs, J. D., Harari, O., Kobold, U., Lee, J. S. & Bernasconi, C. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res. Ther. 15, R204 (2013).
248. Nemeth, E. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 113, 1271–1276 (2004).
249. Kanda, J. et al. Oncostatin M and leukemia inhibitory factor increase hepcidin expression in hepatoma cell lines. Int. J. Hematol. 90, 545–552 (2009).
250. Wallenius, V. et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 8, 75–79 (2002).
251. Smolen, J. S. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371, 987–997 (2008).
252. White, U. A. & Stephens, J. M. The gp130 receptor cytokine family: regulators of adipocyte development and function. Curr. Pharm. Des. 17, 340–346 (2011).
253. Cron, L., Allen, T. & Febbraio, M. A. The role of gp130 receptor cytokines in the regulation of metabolic homeostasis. J. Exp. Biol. 219, 259–265 (2016).
254. Kraakman, M. J. et al. Targeting gp130 to prevent inflammation and promote insulin action. Diabetes Obes. Metab. 15, 170–175 (2013).
255. Gloaguen, I. et al. Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proc. Natl Acad. Sci. USA 94, 6456–6461 (1997).
256. Sleeman, M. W. et al. Ciliary neurotrophic factor improves diabetic parameters and hepatic steatosis and increases basal metabolic rate in db/db mice. Proc. Natl Acad. Sci. USA 100, 14297–14302 (2003).
257. Ettinger, M. P. et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 289, 1826–1832 (2003).
258. Sadagurski, M. et al. Human IL6 enhances leptin action in mice. Diabetologia 53, 525–535 (2010).
259. Ellingsgaard, H. et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat. Med. 17, 1481–1489 (2011).
260. Matthews, V. B. et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 53, 2431–2441 (2010).
261. White, J. P. et al. IL-6 regulation on skeletal muscle mitochondrial remodeling during cancer cachexia in the ApcMin/+ mouse. Skelet Muscle 2, 14 (2012).
262. + and membrane potential, an alternative pathway for Interleukin 6 to regulate CD4 cell effector function. Elife 4, e06376 (2015).
263. Moreno-Aliaga, M. J. et al. Cardiotrophin-1 is a key regulator of glucose and lipid metabolism. Cell Metab. 14, 242–253 (2011).
264. Knudsen, J. G. et al. Role of IL-6 in exercise training- and cold-induced UCP1 expression in subcutaneous white adipose tissue. PLOS One 9, e84910 (2014).
265. Sánchez-Infantes, D. et al. Oncostatin m impairs brown adipose tissue thermogenic function and the browning of subcutaneous white adipose tissue. Obes. (Silver Spring) 25, 85–93 (2017).
266. Ott, V., Fasshauer, M., Dalski, A., Klein, H. H. & Klein, J. Direct effects of ciliary neurotrophic factor on brown adipocytes: evidence for a role in peripheral regulation of energy homeostasis. J. Endocrinol. 173, R1–8 (2002).
267. H17 cells. Nat. Immunol. 18, 74–85 (2017).
268. Skiniotis, G., Boulanger, M. J., Garcia, K. C. & Walz, T. Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor. Nat. Struct. Mol. Biol. 12, 545–551 (2005).